Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis

Graphical AbstractFinerenone demonstrated significant on-treatment reduction in the incidence of all-cause and cardiovascular mortality in patients with chronic kidney disease and type 2 diabetes. Sudden cardiac death was also lowered when the intention-to-treat population was assessed. These effects with finerenone were consistent across Kidney Disease: Improving Global Outcomes risk groups, irrespective of baseline urine albumin-to-creatinine ratio, but were more pronounced in patients with higher baseline estimated glomerular filtration rate.